Skip to main content
Home
  • Home
  • All Sites
  • Contact Us
User account menu
  • Log in

Breadcrumb

  1. Home

What is SARONG?

Full Study Title: Open label randomised controlled trial (RCT) of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer

  • The SARONG study is a multi-centre, open-label, two-arm, parallel design, superiority Randomised Controlled Trial.
  • The study aims to determine whether intensive surveillance after completing curatively intended treatment improves survival and health-related quality of life in patients with oesophageal or gastric cancer.
  • The SARONG study will recruit adults (aged 16 years or over) receiving surgical resection for curatively intended treatment of oesophageal or gastric cancer with or without neoadjuvant/adjuvant chemo(radio)therapy/ immunotherapy.
  • Participant will be randomised to either standard of care or intense surveillance intensive surveillance (including radiological scans (chest and abdomen) and clinical review) every 6 months for 36 months post-randomisation along with an endoscopy at 12 months post-randomisation.

Why do we need a RCT in oesophageal and gastric cancer surveillance?

Open configuration options

  • Currently, national or international guidelines do not provide a routine surveillance for the detection of recurrent disease in patients without symptom or evidence of residual disease after treatment for oesophago-gastric cancer with curative intent (NICE guidelines).
  • There has yet to be a randomised controlled trial that has compared survival between oesophago-gastric cancer patients undergoing different surveillance protocols.
  • There is considerable interest in the oesophago-gastric cancer community in pursuing this.

 

  • University of Oxford logo
  • SITU and NDS Logo
  • NIHR Funded Logo

SARONG received Green Light in June 2023! 

FUNDER & SPONSOR

SARONG is sponsored by the University of Oxford

SARONG is funded by the NIHR Health Technology Assessment (HTA) Programme

SARONG is administreted by the Surgical Intervention Trials Unit (SITU) on behalf of Nuffield Department of Surgical Sciences

RESEARCH REFERENCE NUMBERS

Funder Reference: NIHR134344

Ethics Reference Number: 23/NW/0104

IRAS Number: 319230

Registry: ISRCTN 14417629

CPMS ID: 55905